8-KLeadership ChangesShareholder MattersExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Executive Changes (May 13, 2016)

Filed May 13, 2016For Securities:EW

Summary

This 8-K filing from Edwards Lifesciences (EW) on May 13, 2016, primarily details the outcomes of their 2016 Annual Meeting of Stockholders held on May 11, 2016. The most significant event for investors is the stockholder approval of amendments to the company's Long-Term Stock Incentive Compensation Program. These amendments include an increase in the aggregate share limit by 2,000,000 shares, bringing the total available for issuance to 107,800,000 shares, and an extension of the program's term until February 25, 2026. This indicates a continued commitment to using equity-based compensation to incentivize long-term performance and align executive interests with shareholders. Additionally, the filing confirms the election of all director nominees to one-year terms and provides the results of advisory votes on executive compensation and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2016. The overwhelming support for the director elections and auditor ratification, along with strong approval for the Long-Term Stock Program, suggests broad stockholder confidence in the company's governance and strategic direction.

Key Highlights

  • 1Stockholders approved amendments to the Long-Term Stock Incentive Compensation Program.
  • 2The aggregate share limit under the Long-Term Stock Program was increased by 2,000,000 shares.
  • 3The total share limit for the Long-Term Stock Program now stands at 107,800,000 shares.
  • 4The term of the Long-Term Stock Program was extended through February 25, 2026.
  • 5All director nominees presented at the 2016 Annual Meeting were elected for one-year terms.
  • 6The non-binding advisory proposal on executive compensation received stockholder approval.
  • 7PricewaterhouseCoopers LLP was ratified as the independent public accountant for fiscal year 2016.

Frequently Asked Questions

The primary purpose of this 8-K filing was to report the results of the 2016 Annual Meeting of Stockholders held by Edwards Lifesciences on May 11, 2016. This included voting outcomes on director elections, executive compensation, and amendments to the company's Long-Term Stock Incentive Compensation Program.

The Long-Term Stock Incentive Compensation Program was amended to increase the total number of shares available for issuance by 2,000,000, bringing the aggregate limit to 107,800,000 shares. Additionally, the program's term was extended until February 25, 2026.

The non-binding advisory proposal regarding the compensation of Edwards' named executive officers was approved by the stockholders, with approximately 164,969,852 shares voting 'For' the proposal.

The filing confirms that all director nominees presented at the 2016 Annual Meeting were elected to serve one-year terms. No specific changes or departures of directors were announced in this filing.